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Abstract
Background: Vitamin D status and levels of insulin-like growth factor (IGF)-1 and C-peptide have been implicated in
colorectal carcinogenesis. However, in contrast to vitamin D IGF-1 is not an easily modifiable risk factor.
Methods: Combining data from the Health Professionals Follow up Study (HPFS) and the Nurses’ Health Study cohort (NHS)
additive and multiplicative interactions were examined between plasma 25-hydroxyvitamin D (25(OH)D) and IGF-1, IGFBP-3
as well as C-peptide levels in 499 cases and 992 matched controls. For the various analytes, being high or low was based on
being either above (or equal) or below the medians, respectively.
Results: Compared to participants with high 25(OH)D and low IGF-1/IGFBP-3 ratio (reference group), participants with a
high IGF-1/IGFBP-3 ratio were at elevated risk of colorectal cancer when 25(OH)D was low (odds ratio (OR): 2.05 (95% CI: 1.43
to 2.92), but not when 25(OH)D was high (OR:1.20 (95% CI: 0.84 to 1.71, p(interaction): additive =0.06, multiplicative =0.25).
Similarly, compared to participants with high 25(OH)D and low molar IGF-1/IGFBP-3 ratio and low C-peptide levels
(reference group), participants with a combination of either high IGF-1/IGFBP-3 ratio or high C-peptide were at elevated risk
for colorectal cancer when 25(OH)D was low (OR=1.90, 95% CI: 1.22 to 2.94) but not when 25(OH)D was high (OR=1.15,
95% CI: 0.74 to 1.77, p(interaction): additive=0.004; multiplicative =0.04).
Conclusion: The results from this study suggest that improving vitamin D status may help lower risk of colorectal cancer
associated with higher IGF-1/IGFBP-3 ratio or C-peptide levels.
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Introduction
Both vitamin D status and levels of insulin-like growth factor
(IGF)-1 has been implicated in colorectal carcinogenesis [1–3].
Epidemiological studies have provided consistent support for an
elevated risk of colorectal cancer with lower plasma 25-
hydroxyvitamin D (25(OH)D) levels [4–10]. Several but not all
prospective studies have found evidence for a positive association
between higher levels of IGF-1 or the molar ratio of IGF-1 and its
primary binding protein, IGF-binding protein 3 [11] (IGF-1/
IGFBP-3 ratio) and colorectal and/or colon cancers [12–19].
High levels of insulin (or C-peptide, a marker for insulin
production [20]) may also increase risk of colorectal cancer
[13,16,21–23]. The IGF axis and the insulin axis are biologically
interconnected; for example, insulin may decrease IGF-BP1 levels
[24,25]. Insulin level is strongly modifiable by lifestyle and diet
[26], but IGF-1 is not an easily modifiable risk factor because for
total IGF-1 levels modifiable dietary or lifestyle factors identified
to date have been associated with differences of a relatively small
magnitude [27–38].
Laboratory studies have suggested that 1, 25-dihydroxyvitamin
D3, the biologically active form of vitamin D, might play a role in
the regulation of several IGF binding proteins including the major
binding protein IGFBP-3, indicating that some of the cancer
promoting effects of IGF-1 may be modified by vitamin D [39–
41]. In a study by Ma et al. [42] positive associations between
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28520IGF-1/IGFBP-3 ratio, suggested to be a better marker for
bioavailable IGF-1 [43], and colorectal cancers were most
pronounced among participants who never or rarely drank low-
fat milk, a primary food source for vitamin D.
In previously published studies using data from the Health
ProfessionalsFollow-upStudy(HPFS)andtheNurses’HealthStudy
(NHS) cohorts, higher plasma 25(OH)D levels were significantly
associated with decreased risk and higher IGF-1 levels, the molar
IGF-1/IGFBP-3 ratio and C-peptide levels were associated with
increased risk of colorectal and/or colon cancer [6,8,21]. In this
report, we examined the joint and interactive effects of 25(OH)D,
components of the IGF axis (IGF-1, IGFBP-3) and C-peptide,
combining data from the HPFS and NHS blood cohorts.
Materials and Methods
Study Population
The HPFS cohort was started in 1986 when 51, 129 male U.S.
health professionals aged between 40–75 years were mailed a
questionnaire inquiring about their medical history and lifestyle
factors as well as a 131-item food frequency questionnaire (FFQ).
Since then, follow-up questionnaires have been mailed every two
years and FFQs have been mailed every 4 years. The NHS cohort
was started in 1976 and included 121,700 female nurses residing in
the U.S. who had responded to a mailed questionnaire on lifestyle
and medical history. In 1980, 1984, 1986 and every four years
thereafter participants were also asked to complete a FFQ. More
details regarding the main HPFS and NHS cohorts have been
published elsewhere (HPFS: [44,45] , NHS: [46]). Between 1993–
1995 the HPFS blood cohort was established when 18,225
participants in this cohort provided blood samples and the NHS
blood cohort was established between 1989 and 1990 when 32,826
NHS participants provided blood samples. For more details
regarding blood collection, handling and storage of the blood
samples please refer to (HPFS: [47], NHS: [48]). For this study we
also included laboratory measurements on 134 additional cases
from the NHS diagnosed between June 2000 and October 2008
which had not been included in our previous publications on
associations between plasma 25(OH)D levels and biomarkers of
the IGF and insulin axis and colorectal cancer [6,8,21]. Cases
were identified by study investigators who reviewed medical and
pathology records. Each case was matched to 2 controls by age
(within 3 years of birth), year and month of blood donation (95%
of cases and controls were matched within one month of blood
donation) as well as fasting status (,8 vs. $8 hours since last meal,
NHS only). Controls were required to be alive and free of any
cancer diagnosis (except for non-melanoma skin cancer) at the
time of diagnosis of the case. A total of 499 cases (174 incident
colorectal cancer cases from the HPFS blood cohort and 325 cases
from the NHS blood cohort who were diagnosed after the date of
blood draw and up to January 2002 (HPFS) or October 2008
(NHS)) and 992 matched controls were included in our final
analysis.
This study was approved by the Committee on the Use of
Human Subjects in Research at the Brigham and Women’s
Hospital as well as the Human Subjects Committee of the Harvard
School of Public Health. Return of the questionnaires was
considered to imply informed consent and we also obtained
written consent from each participant to obtain and review
medical records.
Laboratory Analysis
Plasma 25(OH)D levels were assessed at the laboratory of Dr.
Bruce Hollis at the University of South Carolina) by the
radioimmunoassay method as described elsewhere [49]. IGF-1,
IGFBP-3 and C-peptide levels were determined at the laboratory
of Dr. Michael Pollak at the Lady Davis Research Institute of the
Jewish General Hospital and McGill University, using ELISA with
reagents from the Diagnostic Systems Laboratory (Webster, TX).
Each case-control triplet was analyzed in the same batch and the
laboratory personnel were blinded with regard to case control
status. For quality control purposes plasma from pooled blood
samples arranged in triplets were also inserted randomly among
the case-control samples. Using those quality control samples all
mean intra-pair coefficients of variation for plasma 25(OH)D, C-
peptide, IGF-I, and IGFBP-3 were #15%. A molar IGF-I/
IGFBP-3 ratio (IGF-1: 1 ng/mL=0.13 nmol; IGFBP-3: 1 ng/mL
=0.036 nmol) was also calculated in order to better estimate
bioavailable IGF-I [43].
Questionnaire and dietary information
We calculated nutrient intake as the mean from the 1986, 1990
and 1994 FFQs in HPFS and the 1980, 1984, 1986 and 1990
FFQs in NHS [50] (except for calcium and retinol intake which
was calculated using information from the 1990 FFQ in NHS and
1994 FFQ in HPFS and if missing using available information
from the most recent FFQ prior to blood donation). For body mass
index (BMI in kg/m
2) and physical activity we used information
obtained from the questionnaires closest to blood donation, i.e.
1994 in HPFS and 1990 in NHS and if not available from the
most recent questionnaire prior to blood donation. All other
lifestyle variables were updated up to the time of blood donation,
or if not available were carried forward from previous follow-up
questionnaires. The FFQs as well as the anthropometric measures
and physical activity have been validated in previous studies [51–
56]. History of diabetes was assessed using information on self-
reported diabetes from the biennial follow-up questionnaires in
NHS and HPFS. Family history of colorectal cancer was obtained
from the biennial follow-up questionnaires using information from
the 1986, 1990 and 1992 questionnaires (HPFS) and the 1982 and
1988 questionnaires (NHS).
Statistical analysis
To increase statistical power to examine our study question and
because main effects were similar in both cohorts, data from both
blood cohorts were combined. To test whether differences in mean
levels of the plasma analytes between cases and controls were
statistically significant the Wilcoxon signed rank test was used. To
assess the association between medians of each plasma analyte
(based on the median within sex and laboratory batch among
controls) and colorectal or colon cancer, we employed a
conditional logistic regression model. Associations between C-
peptide and colorectal and colon cancers as well as interactions
between C-peptide and plasma 25(OH)D with regard to colorectal
and colon cancers were examined after exclusion of participants
with a self-reported history of diabetes mellitus prior to blood
donation because in these participants C-peptide levels may not be
a good marker for long-term insulin exposure [20]. The following
variables were included in the final multivariable models: BMI
(kg/m
2, continuous), pack-years of smoking (continuous), physical
activity (METs-hr/week, continuous), intake of alcohol (grams/
day), methionine (grams/day), folate (ug/day), retinol (IU/day),
red and processed meat (servings/day), calcium (mg/day) (all
intake covariates as continuous variables), family history of
colorectal cancer (yes vs. no), sex, fasting status (0–2, 3–4, 5–8,
$9 hours since last meal), aspirin use (,2 tablets/week, past use,
$2 tablets/week). In addition, all models for IGF-1 were adjusted
25(OH)D, IGF-1, C-Peptide and Colorectal Cancer
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and a p-value of ,0.05 was considered statistically significant.
Assessment of additive interaction
The methodology used to examine additive interaction has been
reported in more detail in a previous publication from the NHS
cohort [57]. We calculated two measures of additive interaction
previously defined by Rothman [58]: the RERI, i.e. the relative
excess risk due to (additive) interaction ((RR11-RR10-RR01) + 1)
=0; if no interaction; RR11=relative risk among those exposed to
both risk factor #1 and risk factor #2, RR10=relative risk among
those exposed to risk factor #1 but not risk factor #2,
RR01=relative risk among those exposed to risk factor #2 but
not risk factor #1) and based on RERI AP was calculated, i.e. the
proportion of disease among those with both exposures that is
attributable to their interaction (RERI / RR11 =0; if no
interaction).We used SAS programs published by Lundberg and
Andersson [59,60] to calculate these measures of additive
interaction. Confidence intervals for AP were calculated based
on methods described in detail by Hosmer and Lemeshow [61]. A
p-value of ,0.05 for AP was considered statistically significant for
additive interaction.
Assessment of multiplicative interaction
Multiplicative interactions between IGF-1, IGFBP-3, C-Peptide
and plasma 25(OH)D with regard to colorectal and colon cancers
were examined by creating binary variables based on the median
assignment of IGF-1, IGFBP-3 or C-Peptide levels and median
assignment of plasma 25(OH)D levels. Test for multiplicative
interaction was evaluated by adding cross term products of the
pertinent plasma analyte (as binary variables) to the models and
then using the Wald test to calculate the p-value. A p-value of
,0.05 was considered statistically significant for multiplicative
interaction.
Results
Cases had significantly higher mean plasma IGF-1 levels and
molar IGF-1/IGFBP-3 ratio as well as lower plasma 25(OH)D
levels compared to controls (Table 1). Cases and controls did not
differ considerably with regard to most baseline characteristics,
except that cases were more likely to report a family history of
colorectal cancer, were less likely to be aspirin users and had
higher intakes of unprocessed red and processed meats combined
and lower intake of folate, retinol and calcium. Consistent with
results reported in our previous publications on colorectal or colon
cancer from our cohorts [6,8,21], in multivariable analyses higher
IGF-1 and C-peptide levels and IGF-1/IGFBP-3 molar ratio were
significantly associated with higher risk of colorectal and colon
cancer and higher plasma 25(OH)D levels were significantly
associated with lower risk of colorectal and colon cancer (Table 2).
Compared to participants with high 25(OH)D and low IGF-1/
IGFBP-3 ratio (reference group), participants with a high IGF-1/
IGFBP-3 ratio were at elevated risk of colorectal and colon cancers
when 25(OH)D was low (colorectal: odds ratio (OR): 2.05 (95%
CI: 1.43 to 2.92), colon: OR: 2.26 (95% CI: 1.48 to 3.47) but not
when 25(OH)D was high (colorectal: OR: 1.20 (95% CI: 0.84 to
1.71, p(interaction): additive =0.06, multiplicative =0.25, colon:
OR: 1.27 (95% CI: 0.84 to 1.94), p(interaction): additive =0.20,
multiplicative =0.55), Table 3). A similar pattern was observed for
IGF-1. Similarly, compared to participants with high 25(OH)D
and low C-peptide levels (reference group), risk of colorectal and
colon cancers were also elevated when 25(OH)D was low
(colorectal: OR: 1.90 (95% CI: 1.32 to 2.75), colon: OR: 2.31
(95% CI: 1.49 to 3.58), butnot when 25(OH)D was high(colorectal:
OR: 1.18 (95% CI: 0.82 to 1.70), p(interaction); additive =0.10;
multiplicative =0.28, colon: OR: 1.25 (95% CI: 0.81 to 1.91),
p(interaction); additive =0.01; multiplicative =0.11).
Considering previous findings from the NHS blood cohort
which suggested that among women with high IGF-1/IGFBP-3
ratio having also high C-peptide levels did not further increase
risk of colorectal cancer and vice versa [62], we examined
associations between different combinations of molar IGF-1/
IGFBP-3 ratio and C-peptide and plasma 25(OH)D and risk of
colorectal cancers using our combined HPFS and NHS dataset.
As shown in Figure 1, we found that those with high 25(OH)D
did not have a significant increase in risk regardless of IGF-1/
IGFBP-3 ratio or C-peptide level, whereas among those with low
25(OH)D, the participants with high IGF-1/IGFBP-3 ratio or C-
peptide were at elevated risk. Our findings also suggest that
among those with low plasma 25(OH)D levels, having either high
IGF-1/IGFBP-3 ratio or high C-peptide levels increased risk, but
being high in both did not further increase colorectal cancer risk
appreciably. Therefore, to increase statistical efficiency, we
created another binary variable combining molar IGF-1/
IGFBP-3 ratio and C-peptide levels (0= molar IGF-1/IGFBP-
3 ratio below median and C-peptide below median; 1= molar
IGF-1/IGFBP-3 ratio above or equal to median or C-peptide
above or equal to median) and examined additive and
multiplicative interactions between this combined variable and
plasma 25(OH)D levels (above or equal median vs. below
median) with regard to colorectal cancer risk (Figure 2).
Compared to participants with high 25(OH)D and low molar
IGF-1/IGFBP-3 ratio and low C-peptide levels (reference group),
participants with a combination of either high IGF-1/IGFBP-3
ratio or high C-peptide had an almost 2 fold elevated risk for
colorectal and colon cancer (colorectal: OR: 1.90 (95% CI: 1.22
to 2.94, colon: OR: 2.05 (95% CI: 1.23 to 3.41), when 25(OH)D
was low, but not when 25(OH)D was high (colorectal: OR: 1.15
(95% CI: 0.74 to 1.77), p(interaction); additive =0.004;
multiplicative =0.04, colon: OR: 1.13 (95% CI: 0.69 to 1.86),
p(interaction): additive ,0.001; multiplicative =0.02).
Results were similar albeit slightly attenuated compared to those
presented in Figure 2 after we excluded cases diagnosed up to 2
years after blood donation (high IGF-1/IGFBP-3 ratio or high C-
peptide vs. high 25(OH)D and low molar IGF-1/IGFBP-3 ratio
and low C-peptide levels (reference group): colorectal: OR: 1.83
(95% CI: 1.15 to 2.91, p(interaction); additive 0.02, multiplica-
tive=0.09; colon: OR: 1.96 (95% CI: 1.14 to 3.38, p(interaction);
additive 0.008, multiplicative=0.07).
Discussion
In this combined prospective study using nested case-control
data from the HPFS and NHS, we found evidence for statistically
significant additive and multiplicative interactions between plasma
25(OH)D and plasma levels of some components of the IGF axis
and C-peptide with regard to risk of colorectal and colon cancer.
In particular, participants with high 25(OH)D and high C-peptide
or high molar IGF-1/IGFBP-3 ratio did not have a significantly
increased risk of colorectal cancer whereas those with a
combination of low 25(OH)D and high C-peptide or high molar
IGF-1/IGFBP-3 ratio had an about 2 fold increased risk of
developing colorectal cancer when compared to participants with
high 25(OH)D and low C-peptide and low molar IGF-1/IGFBP-3
ratio. Overall, low 25(OH)D levels appeared to be less of a risk
factor when both IGF-1/IGFBP-3 ratio and C-peptide levels were
low.
25(OH)D, IGF-1, C-Peptide and Colorectal Cancer
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(HPFS), 1994–2002 and Nurses’ Health Study (NHS), 1990–2008 (combined).
Characteristics
Cases
(N=499) Controls (N=992) p-value {{{{
Plasma 25(OH)D (ng/mL) 26.2 (10.3) 27.6 (9.8) ,0.001
Plasma IGF-1 (ng/mL) 185 (69.7) 175 (66.3) 0.02
Plasma IGF-BP3 (ng/mL) 4352 (1025) 4291 (1013) 0.22
Molar ratio IGF-1/IGF-BP3 0.15 (0.05) 0.15 (0.05) 0.03
Plasma C-Peptide (ng/mL) (excluding participants with history of diabetes) 2.4 (1.6) 2.3 (1.9) 0.52
Sex {{{{{
Male 174 (34.9) 346 (34.9)
Female 325 (65.1) 646 (65.1) 1.00
Age at blood donation, years {{{{{ 61.7 (8) 61.6 (7.9) 0.95
Hours since last meal {{{{{
,8 hours 129 (25.9) 248 (25.0)
$ 8 hours 335 (67.1) 671 (67.6)
Missing 35 (7.1) 73 (7.4) 0.92
Season of blood donation{{, {{{{{
Winter 179 (35.9) 361 (36.4)
Summer 111 (22.2) 213 (21.5)
Spring/Fall 209 (41.9) 418 (42.1) 0.94
Body mass index (BMI), kg/m
2 $ 26.0 (4.5) 25.5 (4.1) 0.08
Physical activity, MET- hour/wk$ 22.6 (26.1) 23.3 (26.9) 0.93
Aspirin use $
,2 tablets/week 206 (41.3) 325 (32.8)
$2 tablets/week 139 (27.9) 318 (32.1)
Past user 154 (30.9) 349 (35.2) 0.005
Pack-years of smoking { 26.2 (22) 24 (19.6) 0.22
Family history of colorectal cancer
No 410 (82.2) 865 (87.2)
Yes 89 (17.8) 127 (12.8) 0.009
Alcohol, g/d { 8.7 (11.7) 8.4 (11.6) 0.77
Methionine g/d { 1.90 (0.35) 1.90 (0.34)
Total folate intake, mg/d { 424 (187) 456 (212) 0.09
Total vitamin D intake , IU/d {{{ 375 (265) 400 (281) 0.14
Vitamin D from supplements only , IU/d {{{ 145 (229) 159 (229) 0.23
Total calcium intake, mg/d {{{ 908 (340) 953 (357) 0.008
Total retinol intake, IU/d {{{ 3886 (4466) 4241 (4462) 0.02
Total fiber intake, g/d { 18.6 (5.6) 19.2 (6.0) 0.12
Processed meat intake, serv/d { 0.32 (0.35) 0.29 (0.30) 0.11
Unprocessed red meat intake, serv/d { 0.59 (0.33) 0.57 (0.32) 0.18
Unprocessed red and processed meat, serv/d { 0.92 (0.57) 0.86 (0.52) 0.07
Total milk intake, serv/d {{{ 0.98 (1.05) 1.0 (0.99) 0.34
*Numbers in parenthesis indicate standard deviation for means and percentages for frequencies.
$If not noted otherwise (see below) information obtained from 1994 questionnaires (HPFS) or 1990 questionnaire (NHS),
if missing carried forward from most recent questionnaire prior to 1994 (HPFS) or prior to 1990 (NHS).
{For dietary intake: cumulative average intake 1986-1994 (HPFS) and 1980-1990 (NHS), up to 9 participants have missing information.
{Never smokers (N=633) and participants with missing values (N=16) were excluded when calculating means.
{{Season defined as: winter: November, December, January, February, March, summer: June, July, August, September, spring/fall : all other months.
{{{Intake calculated from FFQ in 1994 (HPFS) and FFQ in 1990 (NHS), if missing carried forward from most recent questionnaire prior to 1994 (HPFS) or prior to 1990
(NHS) up to 9 participants have missing information.
{{{{P-values calculated using Wilcoxon signed rank test for plasma biomarkers, Wilcoxon rank sum test for other continuous variables, and x2 tests for categorical
variables.
{{{{{Matching factor
doi:10.1371/journal.pone.0028520.t001
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IGF/IGFBP-3 ratio and high C-peptide to be associated with an
increased risk of colorectal or colon cancer [12–19,21–23]. Both
insulin and IGF-1 may increase colorectal carcinogenesis through
similar mechanisms and pathways, e.g. by increasing proliferation
and decreasing apoptosis [3,26]. In addition, insulin is known to
regulate some aspects of the IGF-1 pathway, for example by
decreasing IGF binding proteins and insulin and IGF-1 receptors
form hybrids and there may be cross-reactivity for insulin and IGF
at the receptor level [24,25,63,64]. Interestingly, as we had
observed previously in the NHS, in the combined NHS and HPFS
cohort, individuals high in either insulin (C-peptide) or IGF-1/
IGFBP-3 ratio appeared to be at higher risk but being high in both
factors did not confer additional risk beyond being high in either
one [21]. We speculate that this pattern suggests that either high
insulin or high IGF-1 level is sufficient to activate the same
pathway. This hypothesis merits further study and confirmation.
Insulin levels are readily modifiable by changes in diet and
lifestyle e.g. by maintaining a healthy weight and increasing
physical activity. Thus, in principle, healthy diet and lifestyle
behaviors could potentially lower insulin levels thereby reducing
risk of colon cancer [26]. On the other hand, for total IGF-1 levels
modifiable dietary or lifestyle factors identified to date have been
associated with differences of a relatively small magnitude [27–38].
In addition, in the HPFS we found that the strongest predictor of
high IGF-1 are diets rich in major sources of animal protein,
including low-fat milk, fish, and poultry, but not red meat, as well
as total vegetable protein [37]. Many of these items are considered
to be components of a healthy diet, so it remains unclear if dietary
patterns that lower growth hormone and IGF-1 levels are desirable
for adults for overall health. Thus, the finding that high 25(OH)D
can substantially lower risk in individuals with high IGF-1/
IGFBP-3 ratio or C-peptide levels is potentially important from a
public health perspective.
We examined both multiplicative and additive interaction.
Although most studies generally emphasize multiplicative interac-
tion, additive interaction may be more relevant from a public
health point of view because it better takes into account differences
in baseline risk. For example, if a protective factor halves the risk
of cancer in two groups, more cases can be prevented in the group
with the highest baseline rate of cancer. We found that although
higher levels of 25(OH)D might be desirable for all, the absolute
number of preventable cases was greater in individuals with high
IGF-1/IGFBP-3 molar ratio or high C-peptide levels. If high IGF-
1 and high insulin underlie in part the high risk of colorectal
cancer in Western countries, our findings suggest that vitamin D
status may be one particularly important factor in such
populations. Further studies are required to test this hypothesis.
The biologic factors underlying our observations are unclear.
Some limited in vitro evidence suggests a direct link between the
IGF-1/insulin axes and vitamin D. For example, laboratory
studies on cultured the human prostate cancer cells the LNCaP
human prostate cancer cell line have suggested that 1,25-
dihydroxyvitamin D3 might influence IGFBP-3 levels [39,40].
1,25-dihydroxyvitamin D3 has been shown to increase expression
of IGFBP-3 possibly by attaching to the BP-3-vitamin D response
element (VDRE) on the IGFBP-3 promoter [40] suggesting that
some of the cancer promoting effects of IGF-1 may be modified by
vitamin D via changes in IGFBP-3 levels. Alternatively, IGF and
insulin may be factors that accelerate colorectal cancer growth and
Table 2. Multivariable adjusted odds ratios (OR) of colorectal and colon cancer by median of plasma analyte level, HPFS and NHS
combined.
Colorectal Cancer Colon Cancer
Plasma Marker Low* High* Low High
IGF-1
Cases/controls 220/497 279/495 156/360 210/367
OR (95% CI)$ 1.00 1.37 (1.05 to 1.78) 1.00 1.52 (1.11 to 2.07)
IGFBP3
Cases/controls 230/496 269/496 171/362 195/365
OR (95% CI) 1.00 0.96 (0.74 to 1.26) 1.00 0.91 (0.68 to 1.25)
Molar IGF-1/IGFBP3 Ratio
Cases/controls 219/497 280/495 159/353 207/374
OR (95% CI) 1.00 1.36 (1.08 to 1.73) 1.00 1.35 (1.02 to 1.79)
C-Peptide {
Cases/controls 197/455 277/460 140/337 211/339
OR (95% CI) 1.00 1.37 (1.05 to 1.78) 1.00 1.58 (1.16 to 2.16)
Vitamin D
Cases/controls 302/498 197/494 224/354 142/373
OR (95% CI) 1.00 0.67 (0.53 to 0.86) 1.00 0.62(0.47 to 0.83)
*Low: below median level; high: equal or above median level.
Median vitamin D levels (controls): HPFS: 29.6 ng/mL; NHS: laboratory batch 1: 23.8 ng/mL; laboratory batch 2: 29.7 ng/mL, laboratory batch 3: 25.5 ng/mL.
$Multivariable adjusted for matching factors (age, year and month of blood donation), body mass index (kg/m2, continuous), packyears of smoking (continuous),
physical activity (MET-hr week, continuous), intake of alcohol, methionine, folate, retinol, red and processed meat, calcium (all intake covariates as continuous variables),
family historyof colorectal cancer (yes vs. no), sex, fasting status (0–2, 3–4, 5–8, $9 hours since last meal), aspirin use (,2 tablets/week, past, $2 tablets/week); models
for IGF-1 were adjusted for IGF-BP3 (in tertiles) and vice versa.
{Models for C-Peptide only included participants without self-reported diabetes mellitus.
doi:10.1371/journal.pone.0028520.t002
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helps reduce proliferation and induce apoptosis through comple-
mentary pathways or mechanisms [66,67].
In our study associations between IGF-1, the molar IGF-1/
IGFBP-3 ratio and C-peptide and colorectal cancers were similar
for men and women. However there is some evidence that
positive associations between higher C-peptide/insulin levels and
colorectal cancers may be more pronounced in men than in
women [68]. Findings from a recent study also suggest that
associations between components of the IGF axis and colorectal
Table 3. Multivariable adjusted ORs and 95% confidence intervals of colorectal and colon cancer by median levels of IGF-1, C-
peptide, IGF-1/IGFBP3 ratio and vitamin D, HPFS and NHS combined.
OR (95% CI) (Cases/
Controls) Colorectal Cancer Colon Cancer
IGF-1 IGF-1
Vitamin D Low High Low High
High 1.00 1.30 1.00 1.58
(85/238) (0.89 to 1.89) (58/183) (1.02 to 2.47)
(112/256) (84/190)
Low 1.42 (0.99 to 2.02) 2.04 1.69 2.53
(135/256) (1.41 to 2.96) (1.09 to 2.62) (1.62 to 3.95)
(167/239) (98/177) (126/177)
Additive IA{{ Multiplicative IA Additive IA Multiplicative IA
p- interaction 0.29 0.65 0.57 0.84
AP{{ 0.16 0.10
(-0.14 to 0.46) (-0.25 to 0.45) Molar IGF-1/IGFBP3 ratio
Vitamin D Low High Low High
High 1.00 1.20 1.00 1.27
(86/228) (0.84 to 1.71) (60/170) (0.84 to 1.94)
(111/266) (82/203)
Low 1.31 2.05 1.50 2.26
(0.92 to 1.87) (1.43 to 2.92) (0.98 to 2.30) (1.48 to 3.47)
(133/269) (169/229) (99/183) (125/171)
Additive IA Multiplicative IA Additive IA Multiplicative IA
p- interaction 0.06 0.25 0.20 0.55
AP 0.26 0.22
(-0.01 to 0.54) (-0.12 to 0.55)
C- peptide C- peptide
Vitamin D Low High Low High
High 1.00 1.18 1.00 1.25
(0.82 to 1.70) (0.81 to 1.91)
(91/240) (97/213) (65/179) (71/163)
Low 1.25 1.90 1.18 2.31
(0.87 to 1.80) (1.32 to 2.75) (0.76 to 1.83) (1.49 to 3.58)
(106/215) (180/247) (75/158) (140/176)
Additive IA Multiplicative IA Additive IA Multiplicative IA
p- interaction 0.10 0.28 0.01 0.11
AP 0.25 0.39
(-0.05 to 0.55) (0.09 to 0.68)
*Low: below median level; high: equal or above median level.
$Multivariable adjusted for matching factors (age, year and month of blood donation), body mass index (kg/m2, continuous), pack-years of smoking (continuous),
physical activity (MET-hr week, continuous), intake of alcohol, methionine, folate, retinol, red and processed meat, calcium (all intake covariates as continuous variables),
family history of colorectal cancer (yes vs. no), sex, fasting status (0–2, 3–4, 5–8, $9 hours since last meal), aspirin use (,2 tablets/week, past, $2 tablets/week); models
for IGF-1 were adjusted for IGF-BP3 (in tertiles) and vice versa.
{Models for C-Peptide only included participants without self-reported diabetes mellitus.
{{Abbreviations: IA=interaction, AP =attributable proportion due to interaction, RERI= relative excess risk due to interaction, RR11=relative risk among those exposed
to both risk factor #1 and risk factor #2, RR10=relative risk among those exposed to risk factor #1 but not risk factor #2, RR01=relative risk among those exposed
to risk factor #2 but not risk factor #1.
AP= RERI / RR11 (=0 if no interaction) with RERI= RR11 - RR10 - RR01 + 1 (=0 if no interaction).
doi:10.1371/journal.pone.0028520.t003
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sex [71]. In that study higher IGF-1 levels were positively
associated with higher risk of colorectal adenoma in men while
IGF-1 levels were not associated with colorectal adenoma in
women.
Findings from a previous study from the NHS and HPFS
suggest that either higher calcium intake or plasma 25(OH)D
levels may be associated with lower fasting C-peptide levels, but
after adjustment for BMI results were not statistically significant
[72]. In that study, a non-significant (additive) interaction between
calcium intake and plasma 25(OH)D levels with regard to C-
peptide was also found, especially in men. We did not study
interactions between calcium intake and components of the IGF
and insulin axes with regard to risk of colorectal cancer because in
our previous analyses on both cohorts [73] inverse associations
between calcium intake and colorectal cancers were limited to
distal colon cancers only and due to small numbers of distal colon
cancers in this study statistical power was limited. Of note, in the
Figure 1. Multivariate odds ratios and 95% confidence intervals of colorectal cancer by different combinations of plasma 25(OH)D,
IGF-1/IGFBP3 ratio (ratio) and C-peptide (high=above or equal median; low = below median), HPFS and NHS combined.
doi:10.1371/journal.pone.0028520.g001
Figure 2. Multivariate adjusted odds ratios and 95% confidence intervals of colorectal cancer by plasma 25(OH)D levels and
combinations of C-peptide levels and molar IGF-1/IGFBP3 ratio, HPFS and NHS combined.
doi:10.1371/journal.pone.0028520.g002
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positive associations between IGF-1 levels and risk was observed
only in those with low milk (and hence calcium) intakes [19]. This
finding is consistent with a previous finding from the Physicians’
Health Study where the positive association between IGF-1/
IGFBP-3 molar ratio and colorectal cancer was strongest in men
with low milk consumption [42]. Because calcium and vitamin D
may interact [74], larger studies are required to examine these
factors simultaneously in combination with IGF-1 and C-peptide
levels.
One of the major strengths of this study includes its prospective
design using blood samples that were obtained prior to diagnosis.
In addition, due to our detailed follow-up and food frequency
questionnaires we were able to take possible confounding due to
known or suspected risk factors for colorectal cancer into account.
One of the major disadvantages of this study is that blood samples
were only obtained at one time point; however, in the HPFS, IGF-
1, IGFBP-3 and molar IGF-1/IGFBP-3 levels were strongly to
moderately correlated when measured in 149 samples donated
about 3 years apart (Spearman partial correlation coefficient after
adjustment for race: IGF-1=0.70, IGFBP-3=0.68, molar ra-
tio=0.59) [75]. For 25(OH)D the respective Pearson correlation
coefficient after adjusting for age, race and season of the year was
0.70 (144 samples) [76]. Another limitation of our study was that
because of the sample size and the examination of multiple factors,
we had to stratify by medians to define ‘‘high’’ and ‘‘low’’ exposure
for 25(OH)D, IGF/IGFBP3 molar ratio, and C-peptide, and we
were unable to look at more extreme ranges (for example, high vs.
low quintiles). Despite this limitation, we were able to observe
statistically significant interactions on both the additive and
multiplicative scales.
To our knowledge no epidemiological study has examined
interactions between components of the IGF axis or C-peptide and
plasma 25(OH)D levels with regard to risk of colorectal cancer.
Therefore, the findings from this prospective study need to be
confirmed in other studies before meaningful conclusions can be
drawn. However, from a public health point of view, if confirmed
these findings would provide a relatively easy way to reduce risk of
colorectal cancer among those with high IGF-1/IGFBP-3 ratio or
high C-peptide levels as vitamin D status is an easily modifiable
risk factor.
In conclusion, if confirmed in other studies, the results from this
study suggest that improving vitamin D status may help lower risk
of colorectal cancer associated with higher IGF-1/IGFBP3 ratio or
C-peptide levels.
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